Borregaard (BRG) CMD 2026 summary
Event summary combining transcript, slides, and related documents.
CMD 2026 summary
30 Sep, 2026Strategic direction and value creation
Focus remains on scaling specialization, productivity, and disciplined capital allocation, prioritizing higher-value products and applications, and expanding capacity for specialty growth, with sharper execution.
Five value creation levers: specialization, capacity, geographic scaling, productivity/cost discipline, and sustainability/regulatory trends.
Geographic expansion targets underpenetrated markets, especially in Asia, Oceania, and Latin America, leveraging proven solutions and local representation.
The business model is highly diversified, resilient, and based on renewable raw materials, supporting consistent returns and margin expansion since IPO.
Continuous improvement and innovation underpin operational efficiency, asset utilization, and higher-value product mix.
Business segment developments and growth opportunities
BioSolutions targets growth by scaling core champions, accelerating emerging stars, moving up the value ladder, and expanding geographically, especially in agriculture, plant nutrition, and animal feed.
Agriculture now accounts for 45% of BioSolutions revenues and is expected to outpace crop protection in value creation by 2028.
Specialty Cellulose/BioMaterials focus on premium niches in regulated and high-purity markets, leveraging a flexible biorefinery platform and ongoing capacity expansion.
Manufacturing improvements include a 5%-10% capacity increase at Sarpsborg by 2027, debottlenecking, energy efficiency, and digitalization/AI for process optimization.
Fine Chemicals and bioethanol have normalized after strong years, with future growth expected from capacity increases and product mix improvements.
Financial guidance and capital allocation
Targets average annual top-line growth of 5% through the business cycle, mainly driven by specialization, product mix improvements, capacity expansion, and price increases.
Aims to maintain an EBITDA margin of 25%, supported by cost discipline, productivity, and profitable investments.
Investment focus is on debottlenecking, climate projects, and productivity improvements, with expansion investments requiring at least a 15% IRR pre-tax.
Dividend policy increased to a payout range of 40%-60% of net profit, with flexibility for extraordinary dividends or buybacks if over-capitalized.
Profitable climate investments are expected to reduce CO2 emissions by 35,000–60,000 t/year and lower annual energy costs by ~45 mNOK.
Latest events from Borregaard
- Scaling high-value bio-based specialities through disciplined growth and investment.BRG
Corporate presentation - Record Q3 EBITDA of NOK 557m; Q4 faces cost, mix and maintenance headwinds.BRG
Q3 2026 - Specialisation, sustainability, and innovation fuel growth in high-value bio-based markets.BRG
Corporate presentation - Q2 revenues and cash flow rose, but Alginor impairment and higher costs hit profit.BRG
Q2 2026 - Sales volumes steady, but cost inflation and market uncertainty drive focus on cost controls.BRG
Pre-close call - Specialisation, innovation, and sustainability drive growth and strong financial performance.BRG
Company presentation - Specialisation, sustainability, and innovation drive growth and value in advanced biorefinery markets.BRG
Corporate presentation - EBITDA fell 16% year-over-year as cost inflation and weaker BioSolutions weighed on results.BRG
Q1 2026 - Specialization, innovation, and sustainability drive growth, backed by strong financials and investment.BRG
CMD 2024